Efficacy Of Roxastat In The Treatment Of Hemodialysis Patients With Erythropoietin Hyporesponsiveness

Objective : bservation of the curative effect of rosastat in hemodialysis patients with hyporesponsiveness to erythropoietin Methods:The clinical data of patients with renal anemia who were on regular hemodialysis in our hospital from February 1,2020 to December 31,2020 were collected.According to the inclusion and exclusion criteria,238 hemodialysis patients were screened,and 19 patients were finally included in the study.General clinical data and blood biochemical indicators of the patients were collected: gender,age,weight,blood pressure,dialysis time and frequency,primary disease,Erythropoietin dosage(calculate the average weekly dosage),red blood cell count,hemoglobin(HGB),hematocrit(HCT),white blood cell count,neutrophil count,lymphocyte count,C-reactive protein(CRP),Albumin(ALB),aspartate aminotransferase(AST),alanine aminotransferase(ALT),creatinine(CR),urea nitrogen(BUN),total cholesterol(TG),triglycerides(TC),low density lipoprotein(LDL),Highdensity lipoprotein(HDL),serum ferritin(SF),parathyroid hormone(PTH),calcium(Ca),phosphorus(P),potassium(K),vitamin B12 and folic acid,the initial dose is determined according to the patient’s weight(Body weight 45～ 60 kg,100 mg/time;body weight> 60 kg,120 mg/time),3 times/week,oral rosastat for 8 weeks,comparison before and after treatment was performed by paired sample t test,P<0.05 is the difference It is statistically significant to compare the changes in the above indicators before and after the patient’s medication,and observe the efficacy of rosastat in the treatment of hemodialysis patients with low erythropoietin response.Results: 1.Compared with the red blood cell count,hemoglobin,hematocrit,ferritin,total cholesterol,and CRP before and after 8 weeks of oral administration of Roxadustat,the difference was statistically significant(P<0.05).2.There was no statistically significant difference in parathyroid hormone,blood calcium,blood phosphorus,blood potassium,vitamin B12,folic acid,triglycerides,low-density lipoprotein,and high-density lipoprotein after 8 weeks of oral administration of roxastat Significance(P≥0.05).Conclusion:1.Oral rosastat can effectively increase the hemoglobin level of hemodialysis patients with hyporesponsiveness to erythropoietin.2.Oral rosastat can reduce cholesterol in hemodialysis patients with hyporesponsiveness to erythropoietin.3.Roxastat can improve the micro-inflammatory state of hemodialysis patients with hyporesponsiveness to erythropoietin.